Press Releases

Print Print   Email Email

Press Releases

All Releases
View Summary Enzon's Debt is Reduced by $116 Million
Mar 8, 2010 		PDF 7.3 KB Add to Briefcase
View Summary Enzon Opens Pediatric Study of PEG-SN38
Feb 24, 2010 		PDF 7.9 KB Add to Briefcase
View Summary Enzon Board of Directors Appoints Executive Committee
Feb 22, 2010 		PDF 7.1 KB Add to Briefcase
View Summary Enzon Reports 2009 Results
Feb 17, 2010 		PDF 27.0 KB Add to Briefcase
View Summary CORRECTING and REPLACING Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webcast to Follow
Feb 9, 2010 		PDF 7.1 KB Add to Briefcase
View Summary Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webcast to Follow
Feb 9, 2010 		PDF 6.9 KB Add to Briefcase
View Summary Enzon Completes Sale of Specialty Pharmaceutical Business
Jan 29, 2010 		PDF 9.0 KB Add to Briefcase
View Summary Enzon Stockholders Approve Sale of Specialty Pharmaceutical Business
Jan 27, 2010 		PDF 7.1 KB Add to Briefcase
View Summary Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
Jan 6, 2010 		PDF 8.2 KB Add to Briefcase
View Summary Enzon Sets Date of Special Meeting of Stockholders to Approve Sale of Specialty Pharmaceutical Business
Dec 22, 2009 		PDF 8.4 KB Add to Briefcase
View Summary Enzon Board Authorizes Share Repurchase of up to $50 Million
Dec 3, 2009 		PDF 7.7 KB Add to Briefcase
View Summary Enzon Presents Data at 2009 EORTC Meeting
Nov 19, 2009 		PDF 13.3 KB Add to Briefcase
View Summary Enzon to Present Data at EORTC-NCI-AACR
Nov 16, 2009 		PDF 10.1 KB Add to Briefcase
View Summary Enzon Announces Agreement to Sell Specialty Pharmaceutical Business
Nov 9, 2009 		PDF 15.3 KB Add to Briefcase
View Summary Enzon Reports Third Quarter 2009 Results
Nov 3, 2009 		PDF 24.5 KB Add to Briefcase
View Summary Enzon to Release Third Quarter 2009 Earnings on Tuesday, November 3, 2009; Conference Call and Webcast to Follow
Oct 28, 2009 		PDF 7.7 KB Add to Briefcase
View Summary UCB's Cimzia(R), the Only PEGylated Anti-TNF, Approved in Europe
Oct 6, 2009 		PDF 17.5 KB Add to Briefcase
View Summary PEGINTRON(R) Receives a Recommendation for Approval from FDA Advisory Committee for a New Application in Melanoma
Oct 5, 2009 		PDF 17.7 KB Add to Briefcase
View Summary Enzon to Present at Newsmakers in the Biotech Industry Conference
Sep 10, 2009 		PDF 17.5 KB Add to Briefcase
View Summary Enzon Reports 2nd Quarter 2009 Results
Aug 4, 2009 		PDF 33.9 KB Add to Briefcase
Showing 1-20 of 285 Page: 1 2 3 ... 15  Next 20
=add release to Briefcase
Search
(ENZN) NASDAQ
Last Trade 10.310
Change(%) price 0.46
Volume 1,303,400
Mar 10, 2010 4:00 PM ET

Sign up to receive Enzon Pharmaceuticals Inc. financial information by email.

click here to sign up

News

  • Details on upcoming events are not yet available.
    click here to be notified of all upcoming events.

  • subscribe to our news feed


    Really Simple Syndication is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates.

  • 03-08-2010

    Enzon's Debt is Reduced by $116 Million

    ­ ­ --Debt converted into an additional 13.5 million shares--
    ­ ­

    click here for more information

  • 02-24-2010

    Enzon Opens Pediatric Study of PEG-SN38

    ­ ­ ­ ­

    click here for more information

  • 02-22-2010

    Enzon Board of Directors Appoints Executive Committee

    ­ ­ Jeffrey Buchalter Steps Down as CEO of Enzon
    ­ ­

    click here for more information

  • 02-17-2010

    Enzon Reports 2009 Results

    ­ ­ --Sale of Specialty Pharmaceutical Business brings over $300 million in value--
    ­ ­

    click here for more information